Novartis CEO plans 80+ submissions for drug approvals through 2022 | Reuters
Structure-Based Design of Potent, Selective, and Orally Bioavailable VPS34 Kinase Inhibitors | Journal of Medicinal Chemistry
Novartis: utili e fatturato robusti, ma l'impatto del Covid si fa sentire - MilanoFinanza.it
Risultati finanziari 2021: Novartis triplica l'utile. Roche fatturato in crescita, ma reddito netto cala (-1%) - AboutPharma
Novartis bilancio 2020: andamento del fatturato e della trimestrale
Novartis to pay $310 million for assets from inflammation specialist IFM | Reuters
Kim Bilancio - President - Greenlayer USA | LinkedIn
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuv
U.S. FDA declines approval of Novartis' cholesterol-lowering drug | Reuters
Novartis Annual Report 2020
Cambio ai vertici di Novartis Italia: Valentino Confalone è il nuovo country president - AboutPharma
Novartis links bonuses to ethics in bid to rebuild reputation | Reuters
Lorenzo Romeo – Product Manager – Novartis | LinkedIn
Blitz e perquisizioni da Novartis - RSI Radiotelevisione svizzera
Kim Bilancio - President - Greenlayer USA | LinkedIn
Novartis bilancio 2022: andamento del fatturato e della trimestrale
Swiss approve insurance cover for Novartis, Gilead cell therapies | Reuters
Novartis Annual Reporting Suite | Novartis
Novartis Annual Reporting Suite | Novartis
Kim Bilancio - President - Greenlayer USA | LinkedIn
Novartis Annual Report 2016
